ASH Annual Meeting and Exposition | Conference

Carfilzomib Combination Significantly Increases PFS in Relapsed Multiple Myeloma

December 7th 2014

Treatment with carfilzomib in combination with lenalidomide and dexamethasone increased PFS by 8.7 months in patients with relapsed multiple myeloma when compared with lenalidomide and dexamethasone alone.

Pembrolizumab Elicits Responses in Classical Hodgkin Lymphoma

December 7th 2014

Treatment with the PD-1 inhibitor pembrolizumab generated responses in 66% of patients with heavily pretreated classical Hodgkin lymphoma.

Blinatumomab Leads to High MRD Response in B-Precursor ALL

December 7th 2014

At least 80% of patients with B-precursor acute lymphoblastic leukemia had a complete minimal residual disease response after a single cycle of treatment with the CD19-directed antibody blinatumomab.

Nivolumab Achieves Encouraging Responses in Refractory Classical Hodgkin Lymphoma

December 6th 2014

In a small phase I trial, most patients with classical Hodgkin lymphoma, having previously failed three or more therapies, responded to the immunotherapy nivolumab.

Dr. Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial

December 6th 2014

A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Dr. Grupp on Optimal Treatment Settings for CAR-Modified T Cells

December 6th 2014

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

ASH 2014 Preview: Checkpoint Inhibition, CAR Modified T Cells, and Novel Therapies

December 1st 2014

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

Dr. van den Brink Highlights Five Abstracts From ASH 2014

December 1st 2014

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of five notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

Dr. Amengual on Novel Therapeutics in Lymphoma

January 21st 2014

Jennifer E. Amengual, MD, discusses the development of novel agents for subtypes of diffuse large b-cell lymphoma.

Dr. Byrd Provides an Update on Ibrutinib in CLL

January 2nd 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), provides an update on ibrutinib for the treatment of CLL.

Dr. Pierluigi Porcu Discusses CTCL Research

December 30th 2013

Pierluigi Porcu, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), discusses early research in CTCL.

Dr. Padron on the SRSF2 Mutation in MDS and CMML

December 23rd 2013

Eric Padron, MD, discusses the SRSF2 mutation in patients with MDS and CMML.

Dr. Shapiro Discusses Bosutinib in CML

December 23rd 2013

Mark Shapiro, MD, PhD, discusses bosutinib as treatment for patients with CML.

Dr. Pardee Provides an Update on CPI-613

December 20th 2013

Timothy S. Pardee, MD, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies.

Dr. Caligiuri on the Anti-KIR Antibody IPH2101

December 19th 2013

Michael A. Caligiuri, MD, CEO, The James Cancer Hospital Solove Research Institute, director, Comprehensive Cancer Center, Ohio State University, discusses the anti-KIR antibody IPH2101 in myeloma and leukemia.

Dr. Zain Discusses Ongoing Trials in T-Cell Lymphomas

December 19th 2013

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Dr. Amengual on Vorinostat and Niacinamide in Lymphoma

December 19th 2013

Jennifer E. Amengual, MD, assistant professor of medicine and developmental therapeutics, member, Center for Lymphoid Malignancies, Columbia University, discusses the potential of the combination of vorinostat and niacinamide as treatment for patients with diffuse large B-cell lymphoma.

Dr. Landgren on Combinations in Newly Diagnosed Myeloma

December 16th 2013

C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

Dr. Mateos on Elderly Patients With Newly Diagnosed MM

December 16th 2013

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

Dr. Berenson on a Study of Pomalidomide in R/R Myeloma

December 13th 2013

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

NEXT PAGE
PREVIOUS PAGE